Rango de valoración compuesto · conservador $11–$12.5 / razonable $14–$16 / optimista $17.6–$18.6. A $18.33, Dentro del rango de valor intrínseco optimista · con muchas expectativas ya descontadas.
Al publicar $18.14 (26 de junio de 2026)
Simulations Plus said it agreed to be acquired by Altaris and is expected to combine with CCG at closing.
Possible impact:May affect merger-premium expectations and pricing of regulatory, shareholder approval and closing risks.
The company posted its fiscal Q2 2026 earnings presentation and webcast materials.
Possible impact:May affect investor views on growth, margins, and the fiscal-year operating cadence.
Automatically summarized from public sources; for context only, not investment advice.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
PróximamenteEsta sección se está completando; vuelve pronto.
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.
